• Prescribing Information
• Indication and Important Safety Considerations
• Site Map
• Register for Updates

• Home
• About ZOMIG
• HCP Resources
  • Migraine Assessment Tools
  • Online Migraine Resources
  • Patient Assistance Programs
  • Convention Calendar
• Resources for Your Patients
• ZOMIG Virtual Rep

Migraine Web Sites and Resources

Use this list as a gateway to other headache and migraine Web sites. Here you will find news, migraine information, and clinical updates.

American Academy of Neurology

Excerpt: "The American Academy of Neurology (AAN) is a medical specialty society established to advance the art and science of neurology, and thereby promote the best possible care for patients with neurological disorders."

For additional information about the treatment of migraine, AAN recommends:

• Headaches: Practical Management

National Headache Foundation (NHF)

Excerpt: "The National Headache Foundation Web site serves as an information resource to headache sufferers, their families, and the healthcare providers who treat them. It is our goal to raise public awareness that headaches are a legitimate biological disease and sufferers should receive understanding and continuity of care."

For CME opportunities and additional information about women’s issues and migraine headaches, NHF recommends:

• Case Studies in the Differential Diagnosis of Headache: Migraine, Sinus Headache, and Episodic Tension-Type Headache
• Women’s Issues in Migraine

American Medical Women's Association

Excerpt: "The American Medical Women’s Association functions at the local, national, and international levels to advance women in medicine and improve women's health. We achieve this by providing and developing leadership, advocacy, education, expertise, mentoring, and strategic alliances. AMWA has been addressing these issues for 90 years."

For additional information about migraine headaches in women, AMWA recommends:

• Migraine and Women’s Health

Indication and Important Safety Considerations

• ZOMIG (zolmitriptan) is indicated for the acute treatment of migraine with or without aura in adults, where a clear diagnosis of migraine has been established
• ZOMIG, like other compounds in this class, should not be given to patients with coronary artery disease (CAD) or for whom unrecognized CAD is predicted by risk factors or to patients with uncontrolled hypertension
• ZOMIG should not be administered to patients with hemiplegic or basilar migraine
• ZOMIG should not be given to patients with cerebrovascular syndromes including (but not limited to) stroke of any type as well as transient ischemic attacks
• The development of a potentially life-threatening serotonin syndrome may occur with triptans, including ZOMIG treatment, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
• There are no adequate and well-controlled studies in pregnant women; therefore ZOMIG should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
• The most common adverse events in clinical trials for ZOMIG and ZOMIG-ZMT were paresthesia, asthenia, nausea, dizziness, pain, chest or neck tightness or heaviness, somnolence, and warm sensation
• The most common adverse events in clinical trials for ZOMIG Nasal Spray were unusual taste, paresthesia, hyperesthesia, and dizziness
• Phenylketonuric patients should be informed that ZOMIG-ZMT 2.5 mg and ZOMIG-ZMT 5 mg contain 2.81 and 5.62 mg of phenylalanine (a component of aspartame), respectively